Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121354 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX
A Phase 1 study of Infection, sponsored by B. Braun Medical.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01121354 is a Phase 1 study of Infection that has completed, run by B. Braun Medical. The registered enrollment target is 24 participants, below the 726-participant average among 41 other Infection trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01121354, a Phase 1 study of Infection, has completed, sponsored by B. Braun Medical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate the safety and pharmacokinetics of Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System to Cefazolin 1.5g for Injection USP and Dextrose Injection USP in daily doses of 6g in healthy adult subjects for 11 days of administration.
Conditions Studied
Interventions
- DRUG Cefazolin 2g for Injection USP and Dextrose Injection USP
- DRUG Cefazolin 1.5g
Study Locations (1)
Maryland
- PAREXEL Early Phase Clinical Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01121354
The ClinicalTrials.gov registry entry for NCT01121354 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 726-participant average among 41 other Infection trials with a reported enrollment target (97% lower). The listed sponsor is B. Braun Medical, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Infection appearing as the primary indexed condition, and to 2 interventions - of which Cefazolin 2g for Injection USP and Dextrose Injection USP is the first listed.
NCT01121354 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01121354 about?
NCT01121354 is a clinical study titled "Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX". The purpose of this study is to demonstrate the safety and pharmacokinetics of Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System to Cefazolin 1.5g for Injection USP and Dextrose Injection USP in daily doses of 6g in healthy adult subjects for 11 days of ad...
What is the current status of trial NCT01121354?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-12. Estimated completion is 2010-02.
What conditions does trial NCT01121354 study?
This clinical trial studies the following conditions: Infection.
What interventions are being tested in trial NCT01121354?
The interventions under investigation include: Cefazolin 2g for Injection USP and Dextrose Injection USP (DRUG), Cefazolin 1.5g (DRUG).
Who is sponsoring clinical trial NCT01121354?
This trial is sponsored by B. Braun Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01121354 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
-
Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration
COMPLETED · Phase 1
-
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
COMPLETED · Phase 1
-
Triple Dye Plus Alcohol Versus Triple Dye Alone for Newborn Umbilical Cord Care
COMPLETED · Phase 1
-
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
COMPLETED · Phase 1
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.